Last reviewed · How we verify
pulmicort respules
At a glance
| Generic name | pulmicort respules |
|---|---|
| Also known as | Budesonide |
| Sponsor | Phoenix Children's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis (PHASE2)
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- The Budesonide in Babies (BiB) Trial (PHASE3)
- Pulmicort Respules on Relapse Rates After Treatment in the ED (PHASE4)
- ARrest RESpiraTory Failure From PNEUMONIA (PHASE3)
- Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19) (PHASE4)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pulmicort respules CI brief — competitive landscape report
- pulmicort respules updates RSS · CI watch RSS
- Phoenix Children's Hospital portfolio CI